Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDIT-CMD trial of diltiazem in symptomatic coronary microvascular dysfunction
NL-OMON59500Phase 4Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of diltiazem in Coronary Small Vessel Disease (CMD) and angina pectoris, sponsored by Radboud University Medical Center. Primary endpoints: Successful treatment with diltiazem, Normalization criteria for IMR and 2 more. Started Nov 2019; status: completed.
02
Drugs
diltiazem
03
Conditions
Coronary Small Vessel Disease (CMD)angina pectoris
Beyond the preview
Go deeper on NL-OMON59500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59500.